Affiliation:
1. Research and manufacturing company “Home оf Pharmacy”
2. Scientific Society “Microbiota”
3. “EUC Clinic” LLC
Abstract
Relevance. Under the influence of endogenous and /or exogenous factors, the intestinal microflora inhabiting all parts of the gastrointestinal tract may change, which disrupts the normal course of physiological processes, and in some cases leads to severe pathological conditions. One of the reasons for the development of intestinal dysbiosis is the use of antibacterial drugs. Thus, the search and development of means for the prevention and treatment of dysbiosis is an urgent task.Goal. The aim of the study was to evaluate the effectiveness of a candidate for a calcium lactate-based drug with repeated intragastric administration on a model of antibiotic-induced dysbiosis in rats.Methods. The study used 40 male Wistar rats (four groups of 10 animals each). A model of antibiotic-induced intestinal dysbiosis was tested in rats by a course of intragastric administration of a combination of amoxicillin and clavulanic acid for 7 days at a dose of 75 mg/kg. The development of dysbiosis was confirmed by a change in the quantitative composition of representatives of the intestinal microbiota. Similarly, for 7 days, the test drug was administered in doses of 5 mg/kg, 25 mg/kg, 125 mg /kg daily 2 hours after the introduction of the pathology inducer. The control group received a 1 % starch solution.Results. The peak of dysbiosis development was recorded on the 4th day of pathology induction. The use of calcium lactate at a dose of 5 mg/kg did not have a significant effect, while in the groups receiving calcium lactate at doses of 25 mg/kg and 125 mg/kg, there was a statistically significant (Mann-Whitney criterion, p < 0.05) decrease in the severity of the pathological process compared with the negative control group.Conclusion. According to the results of this study, it was found that the use of calcium lactate in doses of 25 mg/kg and 125 mg/kg contributed to a faster disappearance of symptoms of dysbiosis and normalization of the intestinal microbiota in comparison with animals that did not receive treatment.
Subject
Pharmacology (medical),Complementary and alternative medicine,Pharmaceutical Science
Reference40 articles.
1. Chen Y, Zhou J, Wang L. Role and Mechanism of Gut Microbiota in Human Disease. Front Cell Infect Microbiol. 2021;11:625913. DOI: 10.3389/fcimb.2021.625913.
2. Evdokimova AG, Zhukolenko LV, Ivanova TB, Stryuk RI. Correction of intestinal microflora synbiotic Maxilac. Experimental and Clinical Gastroenterology. 2019;166(6): 62–69. (In Russ). DOI: 10.31146/1682-8658-ecg-166-6-62-69.
3. Mikrobiota / Ed by Nikonova EL, Popovoi EN. Moscow: Izdatel'stvo Media Sfera; 2007. (In Russ.).
4. Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017;474(11):1823–1836. DOI: 10.1042/BCJ20160510.
5. Industry standard OST 91500.11.0004-2003 «Protokol vedeniya bol'nykh. Disbakterioz kishechnika» (utv. Prikazom Minzdrava Rossii ot 09.06.2003 № 231) (In Russ.). URL: https://docs.cntd.ru/document/1200119089. Ссылка активна на 21.06.2023.